Q Therapeutics 10-Q 31 Jul 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Jul. 31, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'Q Therapeutics, Inc.	'
Entity Central Index Key	'0001366541	'
Document Type	'10-Q	'
Document Period End Date	30-Jun-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Entity Well-known Seasoned Issuer	'No	'
Entity Voluntary Filer	'No	'
Entity Current Reporting Status	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	30,296,726
Document Fiscal Period Focus	'Q2	'
Document Fiscal Year Focus	'2014	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Cash	$1,400,867	$142,532
Receivables, net of allowance of $28,800 as of June 30, 2014 and December 31, 2013	500,216	5,556
Prepaid financing costs, net	'	63,333
Prepaid expenses and other	11,256	10,109
Total current assets	1,912,339	221,530
Property and equipment, net	28,835	27,999
Other assets	'	7,513
Total assets	1,941,174	257,042
Current liabilities:	'	'
Accounts payable	561,058	2,364,001
Accrued liabilities	94,901	81,156
Accrued compensation	549,624	353,950
Notes payable	'	500,000
Derivative liabilities	143,634	'
Total current liabilities	1,349,217	3,299,107
Commitments (Note 8)	'	'
Stockholders' equity (deficit):	'	'
Common stock, $0.0001 par value: 100,000,000 shares authorized; 30,271,726 and 24,936,833 shares outstanding as of June 30, 2014 and December 31, 2013, respectively	3,027	2,494
Additional paid-in capital	26,375,235	20,836,811
Accumulated deficit	-25,786,305	-23,881,370
Total stockholders' equity (deficit)	591,957	-3,042,065
Total liabilities and stockholders' equity (deficit)	$1,941,174	$257,042

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (Unaudited) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Condensed Consolidated Balance Sheets [Abstract]	'	'
Receivables, allowance for doubtful accounts	$28,800	$28,800
Common stock, par value (in Dollars per Share)	$0.00	$0.00
Common stock, shares authorized (in Shares)	100,000,000	100,000,000
Common stock, shares outstanding (in Shares)	30,271,726	24,936,833

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Condensed Consolidated Statements of Operations [Abstract]	'	'	'	'
Grant revenues	$500,216	$6,785	$500,216	$12,286
License fees and other revenues	2,400	'	2,400	'
Total operating revenues	502,616	6,785	502,616	12,286
Cost of revenues	800	'	800	'
Gross profit	501,816	6,785	501,816	12,286
Operating expenses:	'	'	'	'
Research and development	782,939	139,838	1,267,083	270,947
General and administrative	468,871	376,871	1,052,732	751,590
Total operating expenses	1,251,810	516,709	2,319,815	1,022,537
Operating loss	-749,994	-509,924	-1,817,999	-1,010,251
Other income (expense):	'	'	'	'
Interest expense	-8,304	-325	-110,722	-650
Reduction in derivative liabilities	22,560	'	22,560	'
Other income, net	710	515	1,226	1,888
Total other income (expense), net	14,966	190	-86,936	1,238
Loss before provision (benefit) for income taxes	-735,028	-509,734	-1,904,935	-1,009,013
Provision (benefit) for income taxes	'	'	'	'
Net loss	($735,028)	($509,734)	($1,904,935)	($1,009,013)
Weighted average number of common shares outstanding - basic and diluted (in Shares)	29,182,858	24,803,225	27,468,910	24,790,792
Net loss per common share - basic and diluted (in Dollars per Share)	($0.03)	($0.02)	($0.07)	($0.04)

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Cash flows from operating activities:	'	'
Net loss	($1,904,935)	($1,009,013)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation and amortization	4,779	7,400
Original debt discount	63,333	'
Change in derivative liabilities	-22,560	'
Stock-based compensation	388,257	50,877
Common stock issued for services	42,001	50,000
Warrants issued for services	'	12,852
Decrease (increase) in:	'	'
Receivables	-494,660	474,135
Prepaid expenses and other assets	6,366	-585
Increase (decrease) in:	'	'
Accounts payable and accrued liabilities	969,695	-109,166
Accrued compensation	195,674	99,435
Net cash used in operating activities	-752,050	-424,065
Cash flows from investing activities:	'	'
Purchase of property and equipment	-5,615	-22,356
Cash flows from financing activities:	'	'
Issuance of common stock for cash	2,016,000	'
Net increase (decrease) in cash	1,258,335	-446,421
Cash as of beginning of the period	142,532	794,207
Cash as of end of the period	1,400,867	347,786
Supplemental disclosure of cash flow information:	'	'
Cash paid for interest	429	650
Accounts payable converted to common stock [Member]	'	'
Debt Conversion [Line Items]	'	'
Debt conversion, original debt amount	2,727,030	'
Notes payable converted to common stock [Member]	'	'
Debt Conversion [Line Items]	'	'
Debt conversion, original debt amount	$531,863	'
Accounts payable and notes payable converted to common stock [Member]	'	'
Debt Conversion [Line Items]	'	'
Conversion of debt, shares issued (in Shares)	3,258,893	'
Debt conversion converted instrument warrants issued (in Shares)	3,681,893	'

Organization

Organization	6 Months Ended
	Jun. 30, 2014
Organization [Abstract]	'
Organization	'
	1. Organization
	Q Therapeutics, Inc. (Q Therapeutics) conducts its operations through its wholly owned subsidiary, Q Therapeutic Products, Inc. (Q Products) and Q Products’ wholly owned subsidiary, NeuroQ Research, Inc. (collectively, the Company). Q Therapeutics is a Salt Lake City, Utah-based biopharmaceutical company that is developing human cell-based therapies intended to treat degenerative diseases and injuries of the brain and spinal cord, the primary components of the central nervous system (CNS).
	These potential therapies are based on technology developed by Q Products’ co-founder Mahendra Rao, M.D., Ph.D., a leader in glial stem cell biology, during his tenure at the University of Utah and as Head of the Stem Cell Section in the Laboratory of Neuroscience at the National Institutes of Health (NIH). Dr. Rao was one of the first scientists to identify and seek patent coverage on stem cells and their progeny cells found in the CNS. After licensing Dr. Rao’s technology from the University of Utah and NIH, Q Products commenced operations in the spring of 2004 to develop cell-based therapeutic products that can be sold as “off-the-shelf” pharmaceuticals.

Significant_Accounting_Policie

Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Significant Accounting Policies [Abstract]	'
Significant Accounting Policies	'
	2. Significant Accounting Policies
	The following significant accounting policies are followed in preparing the condensed consolidated financial statements:
	Basis of Presentation and Consolidation
	These unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s Form 10-K filed with the Securities and Exchange Commission (SEC) on April 15, 2014. The results of operations for the three and six-month periods ended June 30, 2014 are not necessarily indicative of the results for the full year ending December 31, 2014. In the opinion of management, all adjustments that are necessary for a fair presentation of the financial information for the interim periods reported have been made. All such adjustments are of a normal recurring nature.
	The accompanying unaudited condensed consolidated financial statements have been prepared by management in accordance with U.S. generally accepted accounting principles (US GAAP), and include all assets and liabilities of Q Therapeutics and its wholly owned subsidiary, Q Products. All material intercompany transactions and balances have been eliminated.
	Liquidity
	The Company has not generated significant revenues and has been focused on developing its products. Historically, the Company has been dependent on government grants and debt and equity raised from individual investors to sustain its operations. The Company’s continued operations will depend on its ability to raise funds through similar sources. There can be no assurance that such capital will be available on favorable terms or at all. If it is unable to raise additional capital, the Company will likely be forced to curtail desired development activities, which will delay the development of its product candidates. The Company’s products have not been approved by the U.S. Food and Drug Administration (FDA) for commercial sale; therefore, the Company has not generated revenues from commercial therapeutic product sales. The Company has incurred losses and used cash for operating activities. As of June 30, 2014, the Company had an accumulated deficit of $25,786,305.
	2014 Financing Transactions
	Between March 7 and April 14, 2014, the Company issued an aggregate of 4,420,530 units, each unit consisting of one share of the Company’s common stock and one warrant to purchase one share of the Company’s common stock, in which the Company received cash consideration of $2,012,500 and settled indebtedness of $2,408,030 (2014 Financing Transactions). The warrants were issued with an initial exercise price of $1.00 per share, are immediately exercisable, and expire in no more than four years. Both the shares of common stock and the warrants issued in the 2014 Financing Transactions have a “down-round” protection provision provided to the investors in the financing. With respect to the common shares and warrants issued in the 2014 Financing Transactions, with certain exceptions, if the Company subsequently issues or sells any shares of common stock or any common stock equivalents pursuant to which shares of common stock may be acquired at a price less than $1.00 per share, then the Company shall promptly issue additional shares of common stock to the investor in an amount such that the subscription price paid, when divided by the total number of shares issued will result in an actual price paid per share of common stock equal to such lower price and with respect to warrants, the warrant exercise price shall be reduced to the lesser price at which the common stock or common stock equivalents were issued. The down-round provisions expire upon the earlier of (1) the effectiveness of a registration statement with the SEC registering the shares of common stock issued and the common shares underlying warrants issued in the 2014 Financing Transactions, or (2) one year after the issuance date.
	On June 30, 2014, the Company issued 854,363 shares of common stock as well as warrants to purchase 1,277,363 shares of common stock resulting from the third tranche of financing in which the Company received cash consideration of $3,500 and settled indebtedness of $850,863. The common stock and warrants have terms similar to those in the 2014 Financing Transactions.
	Use of Estimates
	The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Accordingly, actual results could differ from those estimates. Key estimates include allowances for doubtful accounts receivable, useful lives for property and equipment, valuation allowances for net deferred income tax assets, and valuations for stock-based compensation awards. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances.
	Revenue Recognition and Grants Receivable
	The Company periodically applies for research grants, including as a sub-recipient to grants funded by government agencies through research universities. Grant revenues are recognized as associated expenses are incurred and are billed in conjunction with the terms of the grants. The Company records its grants receivable in accordance with the provisions of the grant agreements. The Company’s grants receivable are considered past due when payment has not been received within 30 days of the invoice date, although certain institutions customarily do not pay within these terms. The amounts of the specific reserves are estimated by management based on various assumptions including the age of the individual receivable, as well as changes in payment schedules and histories. Receivable balances are charged off against the allowance for doubtful accounts when management determines the potential for recovery is remote. Recoveries of receivables previously charged off are recorded when payment is received.
	In June 2014, the Company was notified of a sub-award as part of the fourth and final year of grant funding awarded to The Johns Hopkins University (JHU) from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health. The sub-award for the 2014 grant plan year is $677,864. As of June 30, 2014, $500,216 has been billed and is included in receivables.
	Stock-Based Compensation
	The Company calculates the estimated fair value of its stock options and warrants on the grant date using the Black-Scholes option-pricing model. The Company recognizes stock-based compensation expense as services are provided, which is generally over the vesting period of the individual equity instruments. Expense related to stock options issued in lieu of cash to non-employees for services performed are measured at the fair value of the options on the date they are earned.
	The volatility assumption used in the Black-Scholes option-pricing model is based on the volatility of publicly traded companies in the same industry segment as the Company. The expected lives of the options and warrants granted represent the periods of time that the options granted are expected to be outstanding. The risk free rates for periods within the contractual lives of the options and warrants are based on the U.S. treasury securities constant maturity rate that corresponds to the expected terms in effect at the time of grant. Stock-based compensation is included in general and administrative expense in the statements of operations.
	Net Loss Per Common Share
	Basic net loss per common share (Basic EPS) is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted net loss per common share (Diluted EPS) is computed by dividing net loss by the sum of the weighted average number of common shares outstanding and the dilutive potential common share equivalents then outstanding. Potential dilutive common share equivalents consist of shares issuable upon the exercise of outstanding stock options and warrants to acquire common stock.
	Due to the fact that for all periods presented the Company has incurred net losses, potential dilutive common share equivalents as of June 30, 2014 and 2013, totaling 25,238,364 and 15,969,958, respectively, are not included in the calculation of Diluted EPS because they are anti-dilutive. Therefore, basic net loss per common share is the same as diluted net loss per common share for the three and six months ended June 30, 2014 and 2013.
	Recent Accounting Pronouncements
	The Company has elected early adoption of Accounting Standard Update (ASU) 2014-10, Topic 915, Development Stage Entities, Elimination of Certain Financial Reporting Requirements. ASU 2014-10 removes all incremental financial reporting requirements for development stage entities, including but not limited to, inception-to-date financial information included on the statements of operations, statements of stockholders’ equity (deficit) and statements of cash flows. As a result of the Company’s early adoption, all references to the Company as a development stage entity have been removed. The adoption of this pronouncement has no impact on the Company’s financial position, results of operations or liquidity.

Accounts_Payable

Accounts Payable	6 Months Ended
	Jun. 30, 2014
Accounts Payable [Abstract]	'
Accounts Payable	'
	3. Accounts Payable
	On June 30, 2014, the Company settled indebtedness of $423,000 relating to certain accounts payable (see Note 2).

Accrued_Compensation

Accrued Compensation	6 Months Ended
	Jun. 30, 2014
Accrued Compensation [Abstract]	'
Accrued Compensation	'
	4. Accrued Compensation
	Accrued compensation consists of the following:
		June 30, 2014		December 31, 2013
	Accrued wages	$	458,361	$	278,393
	Accrued vacation expense		91,263		75,557
	Total accrued compensation	$	549,624	$	353,950
	In March 2013, certain of the Company’s executives agreed to defer part, if not all, of their salaries until additional funding is obtained by the Company.

Notes_Payable

Notes Payable	6 Months Ended
	Jun. 30, 2014
Notes Payable [Abstract]	'
Notes Payable	'
	5. Notes Payable
	Between August 12 and September 30, 2013, the Company received $250,000 in cash proceeds resulting from a bridge financing by certain note holders, some of which were also considered affiliates, as evidenced by promissory notes. The notes were issued at 50% of face value, bore interest at the rate of 8% per annum, and matured beginning February 5, 2014.
	In February 2014, the largest note holder agreed to extend the maturity date for its $400,000 note for an additional 180 days, in exchange for certain call right language being removed from warrants the note holder had acquired in 2011. On March 7, 2014, the remaining note holder converted its note totaling $104,000, including interest, into units consisting of one share of common stock and one warrant to purchase a share of common stock as part of the 2014 Financing Transactions (see Note 2).
	In June 2014, the largest note holder converted its notes totaling $427,863, including interest, into units consisting of one share of common stock and one warrant to purchase a share of common stock (see Note 2).
	To date, the Company has recorded interest relating to the notes of $281,862, of which $250,000 pertained to the amortization of the debt discount. As of June 30, 2014, the debt discount has been fully amortized and all notes are paid in full.
	The effective interest rate related to this financing is approximately 156%.

Derivative_Liabilities

Derivative Liabilities	6 Months Ended
	Jun. 30, 2014
Derivative Liability [Abstract]	'
Derivative Liability	'
	6. Derivative Liabilities
	In connection with the 2014 Financing Transactions, the Company recorded a derivative liability related to down-round protection provided to the stockholders in the event that the Company completes another offering of units, similar to those issued in the 2014 Financing Transactions, at a price below $1.00 per share. The down-round provision expires upon the earlier of the effectiveness of a registration statement with the SEC or one year after the issuance date. With the assistance of a third-party valuation specialist, the Company valued the derivative liability pursuant to the accounting guidance of ASC 820-10, Fair Value Measurements.
	Fair values for derivative liabilities are determined using the Monte-Carlo Simulation Model valuation technique. The Monte-Carlo Simulation Model provides for dynamic assumptions regarding volatility and risk-free interest rates within the total period to expected conversion. In addition, management assessed the probabilities of future financing assumptions.
	As defined in Financial Accounting Standards Board (FASB) ASC 820-10, fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, FASB ASC 820-10 establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:
	Level 1	Quoted prices in active markets that are accessible at the measurement date for assets or liabilities.
	Level 2	Other inputs that are observable directly or indirectly, such as quoted prices for similar assets and liabilities or market corroborated inputs.
	Level 3	Unobservable inputs that are used when little or no market data is available, which require the Company to develop its own assumptions about how market participants would value the assets or liabilities.
	Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosure each quarter. Assets and liabilities measured at fair value on a recurring basis as of June 30, 2014 are summarized as follows:
		Fair Value as of June 30, 2014
		Level 1			Level 2		Level 3		Total
	Derivative liabilities	$	—		$	—	$	143,634	$	143,634
	The following table presents the reconciliation of Level 3 liabilities measured at fair value on a recurring basis during the six months ended June 30, 2014.
		Fair Value
		Measurements
		Using Significant
		Unobservable Inputs
		(Level 3)
		Derivative
	Beginning balance, December 31, 2013	$	—
	Issuances:
	Derivative liabilities related to down-round provision of common stock and warrants		166,194
	Reduction in derivative liabilities		(22,560	)
	Ending balance, June 30, 2014	$	143,634
	Given the nature of the derivative liabilities, the carrying amount of $143,634 as of June 30, 2014 was derived from Level 3 inputs and represents management’s best estimate of fair value.
	The valuation assumptions inputs used in the Monte-Carlo Simulation model for the six months ended June 30, 2014 are as follows:
	Threshold barrier	$	1
	Average down-round protection value per unit	$	0.1309
	Probability of down-round offer		> 10%

Stockholders_Equity_Deficit

Stockholders' Equity (Deficit)	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity (Defecit) [Abstract]	'
Stockholders' Equity	'
	7. Stockholders’ Equity (Deficit)
	Common Stock
	Between March 7, 2014 and June 30, 2014, the Company issued in aggregate 5,274,893 shares of common stock to individual investors as part of the 2014 Financing Transactions (see Note 2). The shares of common stock have a down-round provision to the stockholders in the event that the Company sells units similar to those in the previous offering at a price below $1.00 per share. The down-round provision expires upon the earlier of (1) the effectiveness of a registration statement with the SEC or (2) one year after the issuance date.
	Additionally, during the quarter ended June 30, 2014, the Company issued an aggregate of 25,000 shares of common stock in lieu of cash for services. As of June 30, 2014, 30,271,726 shares of common stock are outstanding.
	Stock Options
	The following summarizes the outstanding common stock options and related activity for the six months ended June 30, 2014:
		Number of		Weighted		Weighted
		Options		Average Exercise		Average
				Price Per Share		Remaining Life
						(Years)
	Outstanding as of December 31, 2013		3,865,440	$	0.34		6.98
	Granted		3,319,263		0.7		9.71
	Exercised		—		—		—
	Forfeited		—		—		—
	Outstanding as of June 30, 2014		7,184,703		0.51		7.52
	Exercisable as of June 30, 2014		4,587,619		0.44		6.44
	As of June 30, 2014, options to purchase 668,266 shares of common stock under the 2011 Equity Incentive Compensation Plan were available for future grant. The following summarizes information about stock options outstanding as of June 30, 2014:
	Exercise Price	Numbers of		Weighted		Weighted		Number of		Weighted
		Options		Average		Average		Options		Average
		Outstanding		Remaining		Exercise		Exercisable		Exercise
				Contractual		Price				Price
				Life (Years)
	$ 0.06 - $ 0.08		902,600		4.92	$	0.08		902,600	$	0.08
	$ 0.15 - $ 0.19		2,072,840		5.14		0.17		2,072,840		0.17
	$0.70		3,319,263		9.71		0.7		1,041,346		0.7
	$1.00		890,000		7.59		1		570,833		1
			7,184,703		7.52		0.51		4,587,619		0.44
	As of June 30, 2014, the aggregate intrinsic value of outstanding and exercisable stock options was $3,517,903 and $2,834,528, respectively.
	Stock-based compensation for the three months ended June 30, 2014 and 2013 was $139,437 and $25,439, respectively. Stock-based compensation for the six months ended June 30, 2014 and 2013 was $388,257 and $50,877, respectively. As of June 30, 2014, the Company had $971,607 of unrecognized stock-based compensation expense related to non-vested awards that is expected to be recognized over a weighted-average period of 2.73 years.
	The fair value of each stock-based compensation award granted during the six months ended June 30, 2014 was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:
	Risk-free interest rate		1.62% -2.32%
	Expected stock price volatility		66.30% - 72.94%
	Expected dividend yield		0%
	Expected life of options		5 - 7 years
	Warrants
	In January 2014, the Company issued a warrant to purchase 50,000 shares of common stock to a business consulting firm (see Note 8).
	Between March 7 and June 30, 2014, the Company issued warrants to purchase 5,697,893 shares of common stock as a result of three separate tranches of the 2014 Financing Transactions (see Note 2). The warrants have an initial exercise price of $1.00 per share, have up to a four-year life, are exercisable immediately, and have down-round protection in the event that the Company subsequently sells similar units at a price less than $1.00 per share (see Note 6).
	As of June 30, 2014, 18,053,661 warrants to purchase common stock had been issued and were outstanding with exercise prices ranging from $.046 to $2.75 per share and terms ranging from two to seven years. The weighted average warrant exercise price is $1.28 and the weighted average remaining life is 3.90 years.

Commitments

Commitments	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	8. Commitments
	Advisory Agreement
	In May 2014, the Company and its investor relations firm amended their service agreement such that the consulting firm will receive 25,000 shares of the Company’s common stock each quarter in lieu of cash for services rendered. As of June 30, 2014, 50,000 shares of common stock have been issued under this amendment.
	Supplier Agreement
	In June 2014, the Company amended its letter of understanding with a supplier regarding payment for services regarding its animal safety studies. The amendment addresses the payment terms for the studies and allows the Company to pay up to $500,000 of the study costs with equity instruments. Upon completion of the studies, any outstanding balance owed to the supplier will be converted into a note payable bearing an interest rate of 8% per annum through July 31, 2015, and then escalates to 10% per annum through March 31, 2016, the maturity date of the note.

Subsequent_Events

Subsequent Events	6 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	9. Subsequent Events
	In July 2014, the Company issued 25,000 shares of common stock to an investor relations firm.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2014
Significant Accounting Policies [Abstract]	'
Basis of Presentation and Consolidation, Policy	'
	Basis of Presentation and Consolidation
	These unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in the Company’s Form 10-K filed with the Securities and Exchange Commission (SEC) on April 15, 2014. The results of operations for the three and six-month periods ended June 30, 2014 are not necessarily indicative of the results for the full year ending December 31, 2014. In the opinion of management, all adjustments that are necessary for a fair presentation of the financial information for the interim periods reported have been made. All such adjustments are of a normal recurring nature.
	The accompanying unaudited condensed consolidated financial statements have been prepared by management in accordance with U.S. generally accepted accounting principles (US GAAP), and include all assets and liabilities of Q Therapeutics and its wholly owned subsidiary, Q Products. All material intercompany transactions and balances have been eliminated.
Liquidity, Policy	'
	Liquidity
	The Company has not generated significant revenues and has been focused on developing its products. Historically, the Company has been dependent on government grants and debt and equity raised from individual investors to sustain its operations. The Company’s continued operations will depend on its ability to raise funds through similar sources. There can be no assurance that such capital will be available on favorable terms or at all. If it is unable to raise additional capital, the Company will likely be forced to curtail desired development activities, which will delay the development of its product candidates. The Company’s products have not been approved by the U.S. Food and Drug Administration (FDA) for commercial sale; therefore, the Company has not generated revenues from commercial therapeutic product sales. The Company has incurred losses and used cash for operating activities. As of June 30, 2014, the Company had an accumulated deficit of $25,786,305.
Use of Estimates, Policy	'
	Use of Estimates
	The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities as of the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Accordingly, actual results could differ from those estimates. Key estimates include allowances for doubtful accounts receivable, useful lives for property and equipment, valuation allowances for net deferred income tax assets, and valuations for stock-based compensation awards. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances.
Revenue Recognition and Grants Receivable, Policy	'
	Revenue Recognition and Grants Receivable
	The Company periodically applies for research grants, including as a sub-recipient to grants funded by government agencies through research universities. Grant revenues are recognized as associated expenses are incurred and are billed in conjunction with the terms of the grants. The Company records its grants receivable in accordance with the provisions of the grant agreements. The Company’s grants receivable are considered past due when payment has not been received within 30 days of the invoice date, although certain institutions customarily do not pay within these terms. The amounts of the specific reserves are estimated by management based on various assumptions including the age of the individual receivable, as well as changes in payment schedules and histories. Receivable balances are charged off against the allowance for doubtful accounts when management determines the potential for recovery is remote. Recoveries of receivables previously charged off are recorded when payment is received.
	In June 2014, the Company was notified of a sub-award as part of the fourth and final year of grant funding awarded to The Johns Hopkins University (JHU) from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health. The sub-award for the 2014 grant plan year is $677,864. As of June 30, 2014, $500,216 has been billed and is included in receivables.
Stock-Based Compensation, Policy	'
	Stock-Based Compensation
	The Company calculates the estimated fair value of its stock options and warrants on the grant date using the Black-Scholes option-pricing model. The Company recognizes stock-based compensation expense as services are provided, which is generally over the vesting period of the individual equity instruments. Expense related to stock options issued in lieu of cash to non-employees for services performed are measured at the fair value of the options on the date they are earned.
	The volatility assumption used in the Black-Scholes option-pricing model is based on the volatility of publicly traded companies in the same industry segment as the Company. The expected lives of the options and warrants granted represent the periods of time that the options granted are expected to be outstanding. The risk free rates for periods within the contractual lives of the options and warrants are based on the U.S. treasury securities constant maturity rate that corresponds to the expected terms in effect at the time of grant. Stock-based compensation is included in general and administrative expense in the statements of operations.
Net Loss Per Common Share, Policy	'
	Net Loss Per Common Share
	Basic net loss per common share (Basic EPS) is computed by dividing net loss by the weighted average number of common shares outstanding. Diluted net loss per common share (Diluted EPS) is computed by dividing net loss by the sum of the weighted average number of common shares outstanding and the dilutive potential common share equivalents then outstanding. Potential dilutive common share equivalents consist of shares issuable upon the exercise of outstanding stock options and warrants to acquire common stock.
	Due to the fact that for all periods presented the Company has incurred net losses, potential dilutive common share equivalents as of June 30, 2014 and 2013, totaling 25,238,364 and 15,969,958, respectively, are not included in the calculation of Diluted EPS because they are anti-dilutive. Therefore, basic net loss per common share is the same as diluted net loss per common share for the three and six months ended June 30, 2014 and 2013.
Recent Accounting Pronouncements, Policy	'
	Recent Accounting Pronouncements
	The Company has elected early adoption of Accounting Standard Update (ASU) 2014-10, Topic 915, Development Stage Entities, Elimination of Certain Financial Reporting Requirements. ASU 2014-10 removes all incremental financial reporting requirements for development stage entities, including but not limited to, inception-to-date financial information included on the statements of operations, statements of stockholders’ equity (deficit) and statements of cash flows. As a result of the Company’s early adoption, all references to the Company as a development stage entity have been removed. The adoption of this pronouncement has no impact on the Company’s financial position, results of operations or liquidity.

Accrued_Compensation_Tables

Accrued Compensation (Tables)	6 Months Ended
	Jun. 30, 2014
Accrued Compensation [Abstract]	'
Schedule of Accrued Compensation	'
	Accrued compensation consists of the following:
		June 30, 2014		December 31, 2013
	Accrued wages	$	458,361	$	278,393
	Accrued vacation expense		91,263		75,557
	Total accrued compensation	$	549,624	$	353,950

Derivative_Liabilities_Tables

Derivative Liabilities (Tables)	6 Months Ended
	Jun. 30, 2014
Derivative Liability [Abstract]	'
Schedule of Derivative Liabilities	'
	Assets and liabilities measured at fair value on a recurring basis as of June 30, 2014 are summarized as follows:
		Fair Value as of June 30, 2014
		Level 1			Level 2		Level 3		Total
	Derivative liabilities	$	—		$	—	$	143,634	$	143,634
Schedule of Derivative liability fair value unobservable input reconciliation	'
	The following table presents the reconciliation of Level 3 liabilities measured at fair value on a recurring basis during the six months ended June 30, 2014.
		Fair Value
		Measurements
		Using Significant
		Unobservable Inputs
		(Level 3)
		Derivative
	Beginning balance, December 31, 2013	$	—
	Issuances:
	Derivative liabilities related to down-round provision of common stock and warrants		166,194
	Reduction in derivative liabilities		(22,560	)
	Ending balance, June 30, 2014	$	143,634
Schedule of Derivative Liabilities, Valuation Assumptions	'
	The valuation assumptions inputs used in the Monte-Carlo Simulation model for the six months ended June 30, 2014 are as follows:
	Threshold barrier	$	1
	Average down-round protection value per unit	$	0.1309
	Probability of down-round offer		> 10%

Stockholders_Equity_Deficit_Ta

Stockholders' Equity (Deficit) (Tables)	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity (Defecit) [Abstract]	'
Summary of Outstanding Common Stock Options and Related Activity	'
	The following summarizes the outstanding common stock options and related activity for the six months ended June 30, 2014:
		Number of		Weighted		Weighted
		Options		Average Exercise		Average
				Price Per Share		Remaining Life
						(Years)
	Outstanding as of December 31, 2013		3,865,440	$	0.34		6.98
	Granted		3,319,263		0.7		9.71
	Exercised		—		—		—
	Forfeited		—		—		—
	Outstanding as of June 30, 2014		7,184,703		0.51		7.52
	Exercisable as of June 30, 2014		4,587,619		0.44		6.44
Summary of Stock Options Outstanding	'
	The following summarizes information about stock options outstanding as of June 30, 2014:
	Exercise Price	Numbers of		Weighted		Weighted		Number of		Weighted
		Options		Average		Average		Options		Average
		Outstanding		Remaining		Exercise		Exercisable		Exercise
				Contractual		Price				Price
				Life (Years)
	$ 0.06 - $ 0.08		902,600		4.92	$	0.08		902,600	$	0.08
	$ 0.15 - $ 0.19		2,072,840		5.14		0.17		2,072,840		0.17
	$0.70		3,319,263		9.71		0.7		1,041,346		0.7
	$1.00		890,000		7.59		1		570,833		1
			7,184,703		7.52		0.51		4,587,619		0.44
Schedule of Stock Option Awards, Valuation Assumptions	'
	The fair value of each stock-based compensation award granted during the six months ended June 30, 2014 was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions:
	Risk-free interest rate		1.62% -2.32%
	Expected stock price volatility		66.30% - 72.94%
	Expected dividend yield		0%
	Expected life of options		5 - 7 years

Significant_Accounting_Policie2

Significant Accounting Policies (Narrative) (Details) (USD $)	1 Months Ended	6 Months Ended
	Apr. 14, 2014	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Significant Accounting Policies [Abstract]	'	'	'	'
Deficit accumulated during the development stage	'	$25,786,305	'	$23,881,370
2014 Financing Transactions	'	'	'	'
Aggregate equity units issued of one share of common stock and one warrant to purchase one share of common stock (in Financing Units)	$4,420,530	'	'	'
Proceeds for issuance of common stock units	2,012,500	3,500	'	'
Indebtedness settled	2,408,030	850,863	'	'
Warrants issued, maximum expiration period (in Duration)	'4 years	'	'	'
Weighted average exercise price of warrants (in Dollars per Unit)	1	1.28	'	'
Maximum price of common stock issued at which additional shares must be issued to the investor (in Dollars Per Unit)	1	'	'	'
Period of expiration of downround provision if earlier than the effectiveness date of a registation statement (in Duration)	'	'1 year	'	'
Shares issued to settle indebetedness (in Shares)	'	850,863	'	'
Number of shares purchasable with warrants issued to settle indebtedness (in Shares)	'	1,277,363	'	'
Period of no payment, grant receivable considered as past due (in Duration)	'	'30 days	'	'
Sub-award received to help fund manufacturing and pre-clinical safety studies for Q-Cells for 2012-2013 grant plan year	'	677,864	'	'
Grants receivable, sub-award	'	$500,216	'	'
Anti dilutive securities excluded from EPS calculation (in Shares)	'	25,238,364	15,969,958	'

Accounts_Payable_Narrrative_De

Accounts Payable (Narrrative) (Details) (USD $)	Jun. 30, 2014
Accounts Payable [Abstract]	'
Value of accounts payable settled through equity issuances	$423,000

Accrued_Compensation_Schedule_

Accrued Compensation (Schedule of Accrued Compensation) (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Accrued Compensation [Abstract]	'	'
Accrued wages	$458,361	$278,393
Accrued vacation expense	91,263	75,557
Total accrued compensation	$549,624	$353,950

Notes_Payable_Narrative_Detail

Notes Payable (Narrative) (Details) (USD $)	6 Months Ended		11 Months Ended		0 Months Ended	1 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Sep. 30, 2013	Mar. 06, 2014	Jun. 30, 2014
					Note payable, including interest, converted to equity [Member]	Note payable, including interest, converted to equity [Member]
Notes Payable [Abstract]	'	'	'	'	'	'
Note payable, percentage of face value at issuance (in Percent)	'	'	'	50.00%	'	'
Note payable, annual interest rate (in Percent)	'	'	'	8.00%	'	'
Note payable, maturity date (in Date)	5-Feb-14	'	'	'	'	'
Face amount of note with extended maturity date	$400,000	'	'	'	'	'
Note payable, period of extension of maturity date (in Duration)	'180 days	'	'	'	'	'
Number of shares of common stock in each converted unit (in Shares)	1	'	1	'	'	'
Number of warrants in each converted unit (in Shares)	1	'	1	'	'	'
Note payable, interest recorded	'	'	281,862	'	'	'
Note payable, nominal effective interest rate (in Percent)	156.00%	'	156.00%	'	'	'
Amount of amortization of debt discount	63,333	'	250,000	'	'	'
Debt Conversion [Line Items]	'	'	'	'	'	'
Debt conversion, converted instrument, issuance date (Date)	'	'	'	'	7-Mar-14	30-Jun-14
Debt conversion, original debt amount	'	'	'	'	$104,000	$427,863
Equity units issued, number of common stock shares in each (in Shares)	'	'	'	'	'	$1
Equity units issued, number of warrants in each (in Warrants)	'	'	'	'	'	$1

Derivative_Liabilities_Narrati

Derivative Liabilities (Narrative) (Details) (USD $)	6 Months Ended
	Jun. 30, 2014
Derivative Liability [Abstract]	'
Down round provision, stock price floor applicable to future offering of units, below which down round protection is triggered for first tranche investors (in Dollars per Share)	$1
Derivative liability related to down round provision of common stock units	$143,634
Derivative liability valuation assumption, threshold barrier (in Dollars per Unit)	1
Derivative liability valuation assumption, average down-round protection value per unit (in Dollars per Unit)	0.1309
Derivative liability valuation assumption, maximum probability of down-round offer (in Percent)	10.00%

Derivative_Liabilities_Schedul

Derivative Liabilities (Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis) (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Derivative liability related to down round provision of common stock units	$143,634	'
Fair Value Inputs Level 1 [Member]	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Derivative liability related to down round provision of common stock units	'	'
Fair Value Inputs Level 2 [Member]	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Derivative liability related to down round provision of common stock units	'	'
Fair Value Inputs Level 3 [Member]	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'
Derivative liability related to down round provision of common stock units	$143,634	'

Derivative_Liabilities_Schedul1

Derivative Liabilities (Schedule of Level 3 Liabilities, Fair Value Reconciliation) (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'	'	'
Reduction in derivative liabilities	$22,560	'	$22,560	'
Ending balance	143,634	'	143,634	'
Fair Value Inputs Level 3 [Member]	'	'	'	'
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]	'	'	'	'
Beginning balance	'	'	'	'
Issuances: derivative liability related to down round provision of common stock units	'	'	166,194	'
Reduction in derivative liabilities	'	'	-22,560	'
Ending balance	$143,634	'	$143,634	'

Stockholders_Equity_Deficit_Na

Stockholders' Equity (Deficit) (Narrative) (Details) (USD $)	1 Months Ended	3 Months Ended		4 Months Ended	6 Months Ended
	Jan. 31, 2014	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2014	Jun. 30, 2013	Apr. 14, 2014	Dec. 31, 2013
Common Stock	'	'	'	'	'	'	'	'
Common stock issued (in Shares)	'	'	'	5,334,893	'	'	'	'
Price per share of common stock offered, below which, down-round provision will take effect (in Dollars per Share)	'	'	'	'	$1	'	'	'
Period of expiration of the down-round provision if shorter than the effectiveness of a registration statement with the SEC (in Duration)	'	'	'	'	'1 year	'	'	'
Stock issued in lieu of cash for services (in Shares)	'	25,000	'	'	'	'	'	'
Common stock, shares outstanding (in Shares)	'	30,271,726	'	30,271,726	30,271,726	'	'	24,936,833
Stock Options	'	'	'	'	'	'	'	'
Common shares available for future grant (in Shares)	'	668,266	'	668,266	668,266	'	'	'
Outstanding stock options, aggregate intrinsic value	'	$3,517,903	'	$3,517,903	$3,517,903	'	'	'
Exercisable stock options, aggregate intrinsic value	'	2,834,528	'	2,834,528	2,834,528	'	'	'
Stock-based compensation	'	139,437	25,439	'	388,257	50,877	'	'
Unrecognized stock-based compensation expense related to non-vested awards	'	$971,607	'	$971,607	$971,607	'	'	'
Unrecognized stock-based compensation expense related to non-vested awards, weighted-average period of recognition (in Duration)	'	'	'	'	'2 years 8 months 23 days	'	'	'
Warrants	'	'	'	'	'	'	'	'
Number of warrants issued (in Warrants)	1	'	'	'	'	'	'	'
Common stock issuable on excercise of warrants (in Shares)	50,000	5,697,893	'	5,697,893	5,697,893	'	'	'
Number of 2014 Financing Transaction tranches under which warrants were issued	'	'	'	3	'	'	'	'
Downround protection provision share price floor (in Dollars per Unit)	'	'	'	$1	'	'	'	'
Warrants, outstanding (in Shares)	'	18,053,661	'	18,053,661	18,053,661	'	'	'
Exercise price of warrants (in Dollars per Unit)	'	1	'	1	1	'	1	'
Weighted average exercise price of warrants (in Dollars per Unit)	'	1.28	'	1.28	1.28	'	1	'
Weighted average remaining term of warrants	'	'	'	'	'3 years 10 months 24 days	'	'	'
Warrant issued, life of common stock called (in Duration)	'	'	'	'4 years	'	'	'	'
Minimum [Member]	'	'	'	'	'	'	'	'
Warrants	'	'	'	'	'	'	'	'
Exercise price of warrants (in Dollars per Unit)	'	0.46	'	0.46	0.46	'	'	'
Warrant Term (in Duration)	'	'	'	'	'2 years	'	'	'
Maximum [Member]	'	'	'	'	'	'	'	'
Warrants	'	'	'	'	'	'	'	'
Exercise price of warrants (in Dollars per Unit)	'	2.75	'	2.75	2.75	'	'	'
Warrant Term (in Duration)	'	'	'	'	'7 years	'	'	'

Stockholders_Equity_Deficit_Su

Stockholders' Equity (Deficit) (Summary of Outstanding Common Stock Options and Related Activity) (Details) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]	'	'
Number of Options Outstanding, begining balance (in Shares)	3,865,440	'
Number of Options, Granted (in Shares)	3,319,263	'
Number of Options, Exercised (in Shares)	'	'
Number of Options, Forfeited (in Shares)	'	'
Number of Options Outstanding, ending balance (in Shares)	7,184,703	3,865,440
Number of Options, Exercisable, ending balance (in Shares)	4,587,619	'
Weighted Average Exercise Price Per Share, Outstanding, begining balance (in Dollars per Share)	$0.34	'
Weighted Average Exercise Price Per Share, Granted (in Dollars per Share)	$0.70	'
Weighted Average Exercise Price Per Share, Exercised (in Dollars per Share)	'	'
Weighted Average Exercise Price Per Share, Forfeited (in Dollars per Share)	'	'
Weighted Average Exercise Price Per Share, Outstanding, ending balance (in Dollars per Share)	$0.51	$0.34
Weighted Average Exercise Price Per Share, Exercisable, ending balance (in Dollars per Share)	$0.44	'
Weighted Average Remaining Life, options outstanding (Years) (in Duration)	'7 years 6 months 7 days	'6 years 11 months 23 days
Weighted Average Remaining Life, options granted (Years) (in Duration)	'9 years 8 months 16 days	'
Weighted Average Remaining Life, options exercisable (Years) (in Duration)	'6 years 5 months 9 days	'

Stockholders_Equity_Deficit_Su1

Stockholders' Equity (Deficit) (Summary of Stock Options Outstanding) (Details) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]	'	'
Number of Options Outstanding (in Shares)	7,184,703	3,865,440
Number of Options Exercisable (in Shares)	4,587,619	'
Weighted Average Exercise Price (in Dollars per Share)	$0.51	$0.34
Weighted Average Remaining Life, options outstanding (Years) (in Duration)	'7 years 6 months 7 days	'6 years 11 months 23 days
Weighted Average Exercise Price, Exercisable (in Dollars per Share)	$0.44	'
$0.06 - $0.08 [Member]	'	'
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]	'	'
Number of Options Outstanding, exercise price range (in Shares)	902,600	'
Weighted Average Remaining Contractual Life (Years) (in Duration)	'4 years 11 months 1 day	'
Weighted Average Price Exercise, exercise price range, stock options outstanding (in Dollars per Share)	$0.08	'
Number of Options Exercisable, exercise price range (in Shares)	902,600	'
Weighted Average Price Exercise, exercise price range, options exercisable (in Dollars per Share)	$0.08	'
$0.15 - $0.19 [Member]	'	'
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]	'	'
Number of Options Outstanding, exercise price range (in Shares)	2,072,840	'
Weighted Average Remaining Contractual Life (Years) (in Duration)	'5 years 1 month 21 days	'
Weighted Average Price Exercise, exercise price range, stock options outstanding (in Dollars per Share)	$0.17	'
Number of Options Exercisable, exercise price range (in Shares)	2,072,840	'
Weighted Average Price Exercise, exercise price range, options exercisable (in Dollars per Share)	$0.17	'
Exercise Price $0.70 [Member]	'	'
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]	'	'
Number of Options Outstanding, exercise price range (in Shares)	3,319,263	'
Weighted Average Remaining Contractual Life (Years) (in Duration)	'9 years 8 months 16 days	'
Weighted Average Price Exercise, exercise price range, stock options outstanding (in Dollars per Share)	$0.70	'
Number of Options Exercisable, exercise price range (in Shares)	1,041,346	'
Weighted Average Price Exercise, exercise price range, options exercisable (in Dollars per Share)	$0.70	'
Exercise Price $1.00 [Member]	'	'
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]	'	'
Number of Options Outstanding, exercise price range (in Shares)	890,000	'
Weighted Average Remaining Contractual Life (Years) (in Duration)	'7 years 7 months 2 days	'
Weighted Average Price Exercise, exercise price range, stock options outstanding (in Dollars per Share)	$1	'
Number of Options Exercisable, exercise price range (in Shares)	570,833	'
Weighted Average Price Exercise, exercise price range, options exercisable (in Dollars per Share)	$1	'

Stockholders_Equity_Deficit_St

Stockholders' Equity (Deficit) (Stock-Based Compensation Award Valuation Assumptions) (Details)	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity (Defecit) [Abstract]	'
Risk-free interest rate, minimum (in Percent)	1.62%
Risk-free interest rate, maximum (in Percent)	2.32%
Expected stock price volatility, minimum (in Percent)	66.30%
Expected stock price volatility, maximum (in Percent)	72.94%
Expected dividend yield (in Percent)	0.00%
Expected life of options, minimum (in Duration)	'5 years
Expected life of options, maximum (in Duration)	'7 years

Commitments_Narrative_Details

Commitments (Narrative) (Details)	6 Months Ended
	Jun. 30, 2014
Supplier Agreements [Member]	'
Long Term Purchase Commitment [Line Items]	'
Amount of study costs permitted to be paid in equity under amended letter of understanding	500,000
Note payable interest rate applicable through July 31, 2015, for note payable created through conversion of any outstanding balance under purchase commitment upon conclusion of supplier's final project report (in Percent)	8.00%
Note payable interest rate applicable after July 31, 2015 through March 31, 2016, for note payable created through conversion of any outstanding balance under purchase commitment upon conclusion of supplier's final project report (in Percent)	10.00%
Advisory Agreements [Member]	'
Long Term Purchase Commitment [Line Items]	'
Shares issuable quarterly to consulting firm in lieu of cash for services rendered (in Shares)	25,000
Shares issued io date to consulting firm in lieu of cash for services rendered (in Shares)	50,000

Subsequent_Events_Narrative_De

Subsequent Events (Narrative) (Details) (USD $)	1 Months Ended
	Jul. 31, 2014
Subsequent Event [Line Items]	'
Subsequent event, number of common shares issued (in Shares)	$25,000